Shares of drugmaker Sarepta (SRPT) are higher Tuesday on the back of an upgrade from RBC, but Jim Cramer says he's not adding shares to his portfolio. Cramer says that while it's possible that the company could get a takeover offer, he believes the easy money has been made. "I don't like to come in on top of the easy money being made," says Cramer. Sarepta shares have more than doubled over the past month, following a challenging start to 2016.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.